1David E, Kleine R, William G, et al. Matrix metallproteinases and metastasis[J]. Cancer Chemother Pharmacol,1999,43:42-51.
2Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease[J]. Biological Chemistry Hoppe Seyler, 1995, 376(6):345- 355.
3Sang QX, Birkeda-hansen H, Vanwart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B[J]. Biochim Biophys Acta, 1995, 1251(2): 99-108.
4Stetler-stevenson WG. Matrix metalloproteinase inhibitors, in cancer therapeutics: experimental and clinical agents (ed: Teicher, B) [M].Totowa, NJ: Humana Press Inc. 1997,241- 262.
5Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4[J].J Biol Chem,1996,271 (48) :30375 - 30380.
6Ieng ZS, Guille M. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases[J]. Br J Cancer, 1995,72:575- 579.
7Kleiner D, Stetler-stevenson W. Cancer Chemother Pharmacol, 1999,43(suppl): 42-51.
8Farias E, Ranuncolo S, Cresta C, et al. Plasma metal oproteinase ectivity is enhanced in the ecglobulin fraction of breast and lung cancer patients[J]. Int J Cancer, 2000,89(4):389-394.
9Thomas P, Khokha R, Shepherd FA, et al. Differential expression of MMPs and their inhibitors in non-small cell lung cancer[J]. J Pathol,2000,190(2): 150 - 156.
10Suzuki M, IizasaT, FujisawaT, etal. Expression of matrix metalloproteinases and tissue inhibitor of natrix metalloproteinases in non-small-cell lung cancer[J]. Invasion Metastasis, 98-99, 18 (3):134- 141.
